2020 European Society for Medical Oncology Congress Coverage

Save as Favorite

Sign in to receive recommendations (Learn more)

Every year, the European Society for Medical Oncology Congress brings together clinicians, researchers, and advocates to discuss the latest cancer study results. We’re proud to present our coverage below.

Research News

Early Results Suggest Ibrance Plus Faslodex as First Treatment Improves Outcomes for Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer

Studies Show Conflicting Results With Tecentriq and Chemotherapy for Metastatic Triple-Negative Breast Cancer

Adding Tecentriq to Chemotherapy Before Surgery for Early-Stage Triple-Negative Breast Cancer Improves pCR Rates

Trodelvy Improves Outcomes for Previously Treated Metastatic Triple-Negative Breast Cancer

Piqray Improves Overall Survival for Advanced-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer With PIK3CA Mutation

Adding Verzenio to Hormonal Therapy After Surgery for Early-Stage Breast Cancer With High Risk of Recurrence Reduces That Recurrence Risk

Podcast Episodes

Does Chemotherapy Choice Affect How Well Tecentriq Works Against Breast Cancer?
Leisha Emens, M.D., Ph.D.

Breast Cancer Research at ESMO 2020
Michael Method, M.D.

Verzenio Reduces Recurrence Risk for Certain Early-Stage Breast Cancers
Stephen Johnston, M.D., Ph.D.

---

Can we help guide you?

Create a profile for better recommendations

---

• Breast Self-Exam

  Breast self-exam, or regularly examining your breasts on your own, can be an important way to...

• Tamoxifen (Brand Names: Nolvadex, Soltamox)

  Tamoxifen is the oldest and most-prescribed selective estrogen receptor modulator (SERM)....

• What Is Breast Implant Illness?

  Breast implant illness (BII) is a term that some women and doctors use to refer to a wide range...

---

Beta How does this work? Learn more

Are these recommendations helpful? Take a quick survey